Compare DJCO & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DJCO | IRWD |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 706.2M | 741.8M |
| IPO Year | 1995 | 2009 |
| Metric | DJCO | IRWD |
|---|---|---|
| Price | $522.97 | $3.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.68 |
| AVG Volume (30 Days) | 72.6K | ★ 2.7M |
| Earning Date | 05-18-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.50 | N/A |
| EPS | N/A | ★ 0.16 |
| Revenue | $41,384,000.00 | ★ $298,276,000.00 |
| Revenue This Year | N/A | $41.42 |
| Revenue Next Year | N/A | $16.01 |
| P/E Ratio | ★ N/A | $21.00 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $348.63 | $0.55 |
| 52 Week High | $674.75 | $5.78 |
| Indicator | DJCO | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 37.23 |
| Support Level | $383.43 | $3.15 |
| Resistance Level | $674.75 | $3.93 |
| Average True Range (ATR) | 39.28 | 0.36 |
| MACD | -2.58 | -0.16 |
| Stochastic Oscillator | 53.80 | 33.76 |
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.